Completed PHASE4 INTERVENTIONAL 2-arm NCT00972426

A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients

A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients

Sponsor: Taiwan Otsuka Pharm. Co., Ltd

Conditions Glaucoma

Interventions carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)

Updated 5 times since 2017 Last updated: Sep 1, 2011 Started: Oct 31, 2009 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Glaucoma and is currently completed. Taiwan Otsuka Pharm. Co., Ltd leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taiwan Otsuka Pharm. Co., Ltd

Data source: Taiwan Otsuka Pharm. Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan